Today’s Market Runner: What Will Happen to Acceleron Pharma Inc Next? The Stock Just Increased A Lot

Today's Market Runner: What Will Happen to Acceleron Pharma Inc Next? The Stock Just Increased A Lot

The stock of Acceleron Pharma Inc (NASDAQ:XLRN) is a huge mover today! The stock increased 2.00% or $0.55 during the last trading session, hitting $28.03. About 275,078 shares traded hands. Acceleron Pharma Inc (NASDAQ:XLRN) has risen 6.68% since March 29, 2016 and is uptrending. It has outperformed by 3.20% the S&P500.
The move comes after 5 months positive chart setup for the $1.03 billion company. It was reported on Oct, 31 by Barchart.com. We have $45.97 PT which if reached, will make NASDAQ:XLRN worth $659.20 million more.

Analysts await Acceleron Pharma Inc (NASDAQ:XLRN) to report earnings on November, 2. They expect $-0.57 EPS, down 58.33% or $0.21 from last year’s $-0.36 per share. After $-0.59 actual EPS reported by Acceleron Pharma Inc for the previous quarter, Wall Street now forecasts -3.39% EPS growth.

Acceleron Pharma Inc (NASDAQ:XLRN) Ratings Coverage

Out of 7 analysts covering Acceleron Pharma (NASDAQ:XLRN), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. Acceleron Pharma has been the topic of 10 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Monday, February 1 by Oppenheimer. On Thursday, August 13 the stock rating was initiated by Morgan Stanley with “Overweight”. The rating was maintained by FBR Capital with “Outperform” on Monday, January 18. The stock has “Overweight” rating given by Barclays Capital on Monday, June 13. The stock has “Outperform” rating given by FBR Capital on Friday, January 15. Citigroup initiated Acceleron Pharma Inc (NASDAQ:XLRN) rating on Thursday, September 29. Citigroup has “Neutral” rating and $40 price target. Credit Suisse initiated Acceleron Pharma Inc (NASDAQ:XLRN) on Thursday, January 21 with “Outperform” rating. The firm has “Outperform” rating given on Friday, November 20 by Oppenheimer. On Wednesday, April 27 the stock rating was initiated by Barclays Capital with “Overweight”. Janney Capital initiated the shares of XLRN in a report on Thursday, December 17 with “Neutral” rating.

According to Zacks Investment Research, “Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment decreased to 1.49 in Q2 2016. Its down 0.65, from 2.14 in 2016Q1. The ratio worsened, as 15 funds sold all Acceleron Pharma Inc shares owned while 32 reduced positions. 20 funds bought stakes while 50 increased positions. They now own 28.02 million shares or 2.80% less from 28.83 million shares in 2016Q1.
Moreover, Geode Cap Mngmt Llc has 0% invested in Acceleron Pharma Inc (NASDAQ:XLRN) for 246,359 shares. Moreover, Brown Brothers Harriman has 0% invested in Acceleron Pharma Inc (NASDAQ:XLRN) for 471 shares. Perceptive Advisors Ltd last reported 1.42% of its portfolio in the stock. Ubs Asset Mngmt Americas Inc reported 10,600 shares or 0% of all its holdings. Blackrock Fund Advisors accumulated 1.13 million shares or 0.01% of the stock. Tudor Inv Corporation Et Al last reported 14,140 shares in the company. Mutual Of America Capital Ltd Co accumulated 44,663 shares or 0.03% of the stock. Utd Services Automobile Association has 50,680 shares for 0.01% of their US portfolio. Rhumbline Advisers holds 0% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN) for 27,034 shares. Great West Life Assurance Can owns 5,397 shares or 0% of their US portfolio. Janney Montgomery Scott Limited Liability, a Pennsylvania-based fund reported 7,673 shares. Envestnet Asset holds 4,248 shares or 0% of its portfolio. Credit Suisse Ag holds 389,653 shares or 0.01% of its portfolio. Eagle Asset Mngmt Incorporated accumulated 723,829 shares or 0.17% of the stock. State Of New Jersey Common Pension Fund D last reported 18,000 shares in the company.

Insider Transactions: Since May 18, 2016, the stock had 0 insider buys, and 10 insider sales for $45.10 million net activity. Another trade for 32,270 shares valued at $1.12 million was sold by Ertel Steven D. On Friday, September 30 the insider George Jean sold $30.43M. Shares for $689,017 were sold by Quisel John D on Monday, September 12. 100,000 shares with value of $3.39 million were sold by Knopf John L on Friday, July 1. On Monday, May 23 MCLAUGHLIN KEVIN F sold $860,200 worth of the stock or 25,300 shares. On Thursday, October 6 the insider Kumar Ravindra sold $1.78 million. On Friday, July 1 Sherman Matthew L sold $903,143 worth of the stock or 26,000 shares.

More news for Acceleron Pharma Inc (NASDAQ:XLRN) were recently published by: Marketwatch.com, which released: “Acceleron Pharma tabs Bayer exec as next CEO” on September 27, 2016. Businesswire.com‘s article titled: “Acceleron Pharma to Webcast Conference Call of Third Quarter 2016 Financial …” and published on October 27, 2016 is yet another important article.

XLRN Company Profile

Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The Company’s segment operates through discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company’s research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-b) protein superfamily. The Firm focuses on discovering and developing therapeutic candidates that target a group of approximately 30 secreted proteins, or ligands, that are collectively referred to as the TGF-b superfamily. These ligands bind to subsets of 12 different receptors on the surface of cells, triggering intra-cellular changes in gene expression that guide cell growth and differentiation. The TGF-b superfamily ligands and their receptors represent an under-explored and diverse set of drug targets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment